Attempting to Avoid Chemotherapy in CLL with Lenalidomide and Rituximab

from Journal of Clinical Oncology (JCO) Podcast

The current study, reporting on the upfront use of lenalidomide and rituximab in CLL, suggests high response rates and excellent tolerability in younger as well as older patients, albeit with a modest median progression-free survival.

Episode metadata supplied by the publisher feed · Published May 27, 2014

Embed this episode

Attribution link and audio player

NOW PLAYING

Attempting to Avoid Chemotherapy in CLL with Lenalidomide and Rituximab

0:00 8:59

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Journal of Clinical Oncology (JCO) Podcast?

This episode is 8 minutes long.

When was this Journal of Clinical Oncology (JCO) Podcast episode published?

This episode was published on May 27, 2014.

Can I download this Journal of Clinical Oncology (JCO) Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!